Group 1 - The company reported a revenue of RMB 2.7 billion for the six months ending June 30, 2025, representing a year-on-year increase of 62.19% [1] - The net profit attributable to the company's owners was RMB 746 million, an increase of 52.74% year-on-year, with basic earnings per share of RMB 0.62 [1] - The revenue growth was driven by the active development of the global antibody-drug conjugate (ADC) and broader bioconjugate markets, leading to an increase in both customer and project numbers [1] Group 2 - The CRDMO business showed strong momentum in the first half of 2025, with increasing global demand for its services, having empowered a total of 563 global clients [2] - The company has successfully secured 11 process validation (PPQ) projects and one commercial stage project [2] - The company has been recognized as the "Best CDMO" at the World ADC awards for 2023 and 2024, highlighting its leading position in providing technology-driven comprehensive services for ADCs and bioconjugates [2] Group 3 - The company is expanding its production capacity and attracting talent to prepare for the growing demand for bioconjugate CRDMO services [2] - The GMP release of the XDP3 formulation workshop and the expansion of the Wuxi base, including the ongoing construction of the XDP5 formulation workshop, are progressing as planned [2] - The completion of these expansions will provide additional monoclonal antibody, drug substance (DS), and drug product (DP) production lines, laboratories, and office space [2]
药明合联发布中期业绩，股东应占纯利7.46亿元，同比增加52.74%